会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 42. 发明授权
    • Plasma display apparatus
    • 等离子显示装置
    • US07250725B2
    • 2007-07-31
    • US11364086
    • 2006-03-01
    • Tomihide NomotoKazunobu KojimaAkira Mizuno
    • Tomihide NomotoKazunobu KojimaAkira Mizuno
    • H01J17/49
    • H05K5/02
    • A plasma display apparatus is equipped with a signal input terminal responsive to a user's application. The plasma display apparatus includes a panel including a pair of substrates, wherein at least one of the substrates is transparent. The substrates are placed opposite to each other to form a discharge space in between, and electrodes are provided to the substrate. The plasma display apparatus also includes a display driving circuit block, disposed on a chassis and equipped with at least one signal inputting connector which applies a signal to the panel to perform displaying, and an input signal circuit block detachable to the signal inputting connector of the display driving circuit block.
    • 等离子体显示装置配备有响应于用户应用的信号输入端子。 等离子体显示装置包括具有一对基板的面板,其中至少一个基板是透明的。 基板彼此相对设置以在其间形成放电空间,并且电极被提供到基板。 等离子体显示装置还包括显示驱动电路块,该显示驱动电路块设置在机架上,并配有至少一个信号输入连接器,该信号输入连接器向面板施加信号以进行显示;以及输入信号电路块,其可拆卸到信号输入连接器 显示驱动电路块。
    • 43. 发明申请
    • Ionized gas current emission type dust-free ionizer
    • 电离气体发射型无尘电离器
    • US20060279897A1
    • 2006-12-14
    • US11507917
    • 2006-08-22
    • Akira MizunoAkio SugitaMasanori SuzukiTomokatsu SatoToshihiko HinoHaruyuki Togari
    • Akira MizunoAkio SugitaMasanori SuzukiTomokatsu SatoToshihiko HinoHaruyuki Togari
    • H01H47/00
    • H01T23/00
    • The ionizer of the present invention comprises a chamber which has an ionization part that ionizes a portion of an ion carrier gas that is supplied to the interior of this chamber, and a blowing part which feeds the ion carrier gas toward a charged body. The ionization part is constructed from an ionization source which is contained in the chamber, and a control device which is connected with this ionization source via a high-voltage cable. Either the generating part of a soft X-ray generating device, the generating part of a low-energy electron beam generating device or the generating part of an ultraviolet radiation generating device is used as the ionization source. The control device, the connecting part between the control device and the high-voltage cable and the connecting part between the ionization source and the high-voltage cable are formed with an explosion-proof structure.
    • 本发明的电离器包括具有离子化部分的室,该离子化部分离子化供应到该室内的离子载体气体的一部分,以及将离子载气朝向带电体供给的吹送部。 离子化部分由容纳在室中的电离源构成,以及通过高压电缆与该电离源连接的控制装置。 使用软X射线产生装置的产生部分,低能电子束产生装置的产生部分或紫外线辐射产生装置的产生部分作为电离源。 控制装置,控制装置和高压电缆之间的连接部分以及电离源和高压电缆之间的连接部分由防爆结构形成。
    • 44. 发明授权
    • Plasma display apparatus
    • 等离子显示装置
    • US07091665B2
    • 2006-08-15
    • US10311433
    • 2002-06-12
    • Tomihide NomotoKazunobu KojimaAkira Mizuno
    • Tomihide NomotoKazunobu KojimaAkira Mizuno
    • H01J17/49H01J17/34H01J17/35
    • H05K5/02
    • A plasma display apparatus is equipped with a signal input terminal responsive to a user's application. The plasma display apparatus includes a panel including a pair of substrates, wherein at least one of the substrates is transparent. The substrates are placed opposite to each other to form a discharge space in between, and electrodes are provided to the substrate. The plasma display apparatus also includes a display driving circuit block, disposed on a chassis and equipped with at least one signal inputting connector which applies a signal to the panel to perform displaying, and an input signal circuit block detachable to the signal inputting connector of the display driving circuit block.
    • 等离子体显示装置配备有响应于用户应用的信号输入端子。 等离子体显示装置包括具有一对基板的面板,其中至少一个基板是透明的。 基板彼此相对设置以在其间形成放电空间,并且电极被提供到基板。 等离子体显示装置还包括显示驱动电路块,该显示驱动电路块设置在机架上,并配有至少一个信号输入连接器,该信号输入连接器向面板施加信号以进行显示;以及输入信号电路块,其可拆卸到信号输入连接器 显示驱动电路块。
    • 49. 发明授权
    • Intermittent claudication therapeutic drugs comprising pyrroloazepines
    • 间歇性跛行治疗药物,包括吡咯并氮
    • US06288056B1
    • 2001-09-11
    • US09673514
    • 2000-10-17
    • Atsuto OgataNorio InomataAkira Mizuno
    • Atsuto OgataNorio InomataAkira Mizuno
    • A61K3155
    • A61K31/55A61K31/496
    • A method of treating or improving intermittent claudication, which comprises administering, to a patient with intermittent claudication, a pyrroloazepine derivative or a pharmacologically acceptable salt thereof, said pyrroloazepine derivative being represented by the following formula (I): wherein the dotted line indicates existence or nonexistence of a bond; when the bond of the dotted line exists, X does not exist, and, when the bond of the dotted line does not exist, X represents a hydrogen atom, a hydroxy group or a group OR1 in which R1 represents a substituted or unsubstituted alkyl group; Y represents a linear or branched, substituted or unsubstituted alkyl group; Z1 and Z2 are the same or different and each independently represent a hydrogen atom, a hydroxy group or a halogen atom; and W represents a hydrogen atom or a methyl group.
    • 一种治疗或改善间歇性跛行的方法,其包括对间歇性跛行的患者施用吡咯并氮衍生物或其药理学上可接受的盐,所述吡咯并氮衍生物由下式(I)表示:其中虚线表示存在或 不存在债券; 当存在虚线的键时,X不存在,并且当虚线的键不存在时,X表示氢原子,羟基或其中R 1表示取代或未取代的烷基的基团OR 1 ; Y表示直链或支链的取代或未取代的烷基; Z 1和Z 2相同或不同,各自独立地表示氢原子,羟基或卤素原子; W表示氢原子或甲基。
    • 50. 发明授权
    • Pyrroloazepine derivatives
    • 吡咯并氮衍生物
    • US06258805B1
    • 2001-07-10
    • US09312713
    • 1999-05-17
    • Akira MizunoMakoto ShibataTomoe IwamoriTetsuo ShimamotoKyoko NakanishiNorio Inomata
    • Akira MizunoMakoto ShibataTomoe IwamoriTetsuo ShimamotoKyoko NakanishiNorio Inomata
    • A61K3155
    • C07D487/04C07D207/34
    • A method for treating a circulatory disease or condition in a mammal, which entails administering to the mammal an effective amount of a compound of the formula (I) or a pharmaceutically acceptable salt thereof: wherein the ring P represented by  is a pyrrole ring having the following structure: wherein R1 represents C1-C8 alkyl, C3-C8 cycloalkyl, C4-C8 cycloalkyl-alkyl, C6-C14 aryl or C7-C22 aralkyl, which are optionally substituted; and R2 represents H or C1-C8 alkyl, which is optionally substituted; the dashed line indicates the presence or absence of a bond; and, when the bond is present, Z2 is not present and Z1 represents H, but, when the bond is absent, Z1 and Z2 are both H; Z1 represents H and Z2 represents a group OR3, in which R3 represents H, C1-C8 alkyl, or C7-C22 aralkyl, which are optionally substituted; Z1 and Z2 both represent groups SR4, in which R4 represents C1-C8 alkyl or C7-C22 aralkyl, which are optionally substituted; or Z1 and Z2 are combined together to represent O, a group NOR5, in which R5 represents H, or C1-C8 alkyl or C2-C3 alkylenedithio, which are optionally substituted; A represents alkylene, alkenylene or alkynylene; and Y represents a group in which W is CH, C═ or N, m is for 0 or 1, n is for 1, 2 or 3, G is O, S, C═O, sulfinyl, sulfonyl, alkylene, alkenylene or acetal; E1 and E2 is H or C1-C8 alkyl; and D represents an aromatic hydrocarbon or an aromatic heterocyclic ring. The compound (I) has strong serotonin-2 receptor antagonistic action and low toxicity and less side effects, and is therapeutically useful in the treatment of circulatory diseases and/or conditions related thereto.
    • 一种用于治疗哺乳动物的循环系统疾病或病症的方法,其需要向哺乳动物施用有效量的式(I)化合物或其药学上可接受的盐:其中由表示的环P是具有以下基团的吡咯环 结构:其中R 1表示任选取代的C 1 -C 8烷基,C 3 -C 8环烷基,C 4 -C 8环烷基 - 烷基,C 6 -C 14芳基或C 7 -C 22芳烷基; 并且R 2表示H或被任选取代的C 1 -C 8烷基; 虚线表示存在或不存在键; 当存在键时,Z 2不存在,Z1表示H,但不存在键时,Z 1和Z 2均为H; Z1表示H,Z2表示OR3,其中R3表示H,任选取代的C 1 -C 8烷基或C 7 -C 22芳烷基; Z 1和Z 2均表示SR 4,其中R 4表示任选取代的C 1 -C 8烷基或C 7 -C 22芳烷基; 或Z 1和Z 2组合在一起表示O,其中R 5表示H的基团NOR 5或任选被取代的C 1 -C 8烷基或C 2 -C 3亚烷基二硫基; A表示亚烷基,亚烯基或亚炔基; 并且Y表示W为CH,C =或N的基团,m为0或1,n为1,2或3,G为O,S,C = O,亚磺酰基,磺酰基,亚烷基,亚烯基或亚磺酰基 乙缩醛 E1和E2是H或C1-C8烷基; D表示芳族烃或芳香族杂环。 化合物(I)具有强的5-羟色胺-2受体拮抗作用和低毒性和较少的副作用,并且在治疗循环系统疾病和/或与之有关的病症中是治疗上有用的。